Related references
Note: Only part of the references are listed.POPULATION PHARMACOKINETICS OF AN ANTI-PD-1 ANTIBODY, PENPULIMAB IN PATIENTS WITH ADVANCED MALIGNANCIES
Benchao Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Penpulimab, an IgG1 anti-PD-1 antibody with Fc-engineering to eliminate effector functions and with unique epitope and binding properties
B. Li et al.
ANNALS OF ONCOLOGY (2021)
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Li-Tzong Chen et al.
GASTRIC CANCER (2020)
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Junho Kang et al.
CANCER RESEARCH AND TREATMENT (2020)
Targeted Therapies in Advanced Gastric Cancer
Timil H. Patel et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
Jayesh Desai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Lin Shen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Looking to Long-term Survivors for Improved Pancreatic Cancer Treatment
Bridget M. Kuehn
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
Feng-Hua Wang et al.
CANCER COMMUNICATIONS (2019)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Global trends and predictions in hepatocellular carcinoma mortality
Paola Bertuccio et al.
JOURNAL OF HEPATOLOGY (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Immune Checkpoint Inhibitors in Challenging Populations
Douglas B. Johnson et al.
CANCER (2017)
SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016)
M. Martin-Richard et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Share Paper
